Last reviewed · How we verify
NCT05081349
Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
Phase 4 trial testing Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine in Sickle Cell Disease in 91 participants. Completed in 10 July 2021.
10 June 2020
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 91 |
| Start date | 10 January 2017 |
| Primary completion | 10 June 2020 |
| Estimated completion | 10 July 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine — full drug profile →
- Hydroxycarbamide 500 Mg Oral Capsule — full drug profile →
- L-Carnitine, 250 Mg Oral Capsule — full drug profile →
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
Assiut University
Who can join
18 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The role of the combination therapy of hydroxyurea and L-Carnitine was studied in thalassemic patients. nevertheless its role in sickle cell anemia patients was not investigated
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Fatty acid nitroalkenes - Multi-target agents for the treatment of sickle cell disease.
Chowdhury FA, Colussi N, Sharma M, Wood KC, et al · · 2023 · cited 12× · PMID 37907055 · DOI 10.1016/j.redox.2023.102941
Verify or expand the search:
- PubMed search for NCT05081349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05081349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 22 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05081349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing